Dupilumab Under Review for Atopic Dermatitis in Children Aged 5 Years and Younger
The sBLA is supported by data from the phase 3 LIBERTY AD PRESCHOOL study.
The sBLA is supported by data from the phase 3 LIBERTY AD PRESCHOOL study.
Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.
Disparities in dermatology and the role of ethnic skin centers in addressing these issues are discussed with Angela Lamb, MD.
The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.
The largest longitudinal study to date explores the relationship between childhood atopic dermatitis (AD) and height and BMI.
The ADhere trial evaluated lebrikizumab in combination with topical corticosteroids in adults and adolescents with moderate to severe atopic dermatitis.
Less than half of women experiencing hair loss have genetic origins as the cause; possible causes and treatments are reviewed.
The FDA’s Fast Track process allows for expedited review of drugs that are expected to fill an unmet need.
The prevalence and predictors of patient-reported worsening of AD symptoms during pregnancy are examined.
A novel study reports the positive response to oral and topical antifungals for patients with atopic dermatitis (AD) treated with dupilumab who developed facial redness.